Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection
PLOS Pathogens · 09.12.2025 · 21 (12) · e1013709
DOI: 10.1371/journal.ppat.1013709 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 09.12.2025. Verfasst von Ya Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Develo…. Hauptthemen laut MEDLINE: Membrane Proteins, Hepatitis B virus, Antiviral Agents, Hepatitis B, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Initiative for Innovative Medicine.
Abstract (Originalsprache)
Activation of antiviral immune responses against hepatitis B virus (HBV) is essential for the durable control of chronic HBV infection and the functional cure of chronic hepatitis B. As a molecular hub at the interface of innate and adaptive immunity, the stimulator of interferon (IFN) genes (STING) is well suited as a therapeutic target to break the immune tolerance against chronic viral infections and tumors. Using STING knockout and human STING knock-in mouse models, we first demonstrated that STING agonist treatment activated robust innate immune responses in the spleen and liver and efficiently suppressed HBV DNA replication in the livers of AAV-HBV transduced mice in a STING-dependent manner. We further demonstrate that AAV-HBV transduced mice are well tolerated for the long-term treatment of STING agonist diamidobenzimidazole (diABZI) at the optimized dose and dosing schedules. Virological and hepatic bulk and single-cell RNA-seq analyses revealed that diABZI treatment activated immune responses in liver microenvironment and significantly inhibited HBV replication and HBeAg expression. Antibodies against HBV surface antigen (HBsAg), HBs-Ab, became detectable in 1/4 mice after 5 weeks of treatment. In conclusion, our findings imply that diABZI treatment activates a STING-dependent immune response that controls HBV replication in a mouse model of persistent HBV infection and thus establishes a scientific basis for further development of STING agonists as immune therapeutics for the treatment of chronic hepatitis B.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, NHC Key Laboratory of Biotechnology for Microbial Drugs, Instit…
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Yuhuan Li
Förderung
- National Natural Science Foundation of China
- CAMS Initiative for Innovative Medicine
Zitieren
APA
Wang, Y., Wu, S., Li, X., Qiao, L., Wang, H., Yang, G., Yan, H., Wang, K., Jiang, J. D., & Li, Y. (2025). Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection. PLOS Pathogens, 21(12), e1013709. https://doi.org/10.1371/journal.ppat.1013709
Vancouver
Wang Y, Wu S, Li X, Qiao L, Wang H, Yang G, et al. Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection. PLOS Pathogens. 2025;21(12):e1013709. doi:10.1371/journal.ppat.1013709
BibTeX
@article{Wang2025,
author = {Wang, Ya and Wu, Shuo and Li, Xingqiong and Qiao, Lijun and Wang, Huiqiang and Yang, Ge and Yan, Haiyan and Wang, Kun and Jiang, Jian-Dong and Li, Yuhuan},
title = {Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection},
journal = {PLOS Pathogens},
year = {2025},
volume = {21},
number = {12},
pages = {e1013709},
doi = {10.1371/journal.ppat.1013709}
}
EUVIMED